Development asset linked to Summit Therapeutics in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
pharma · Metastatic Colorectal Cancer · Duchenne Muscular Dystrophy · SMMT
Summit Therapeutics
Summit Therapeutics drug portfolio — 32 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
601 Brickell Key Dr, Suite 1000, Miami, Florida 33131, US HQ
2003 Founded
367 Employees
Public company Type
SMMT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 601 Brickell Key Dr, Suite 1000, Miami, Florida 33131, US
- Founded
- 2003
- Employees
- 367
- Programs
- 41
- Drugs
- 32
- Patents
- 20
Summit Therapeutics pipeline
Portfolio lens on 32 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Summit Therapeutics drug portfolio — 32 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
US regulatory status: approved. Mechanism: Surfactant agent.
- Mechanism
- Surfactant agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records. Mechanism: Beta-2 adrenergic receptor antagonist.
- Mechanism
- Beta-2 adrenergic receptor antagonist
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Essential for cellular homeostasis.
- Mechanism
- Essential for cellular homeostasis
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.
-
Development asset linked to Summit Therapeutics in public FDA and regional records.